m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG00234)
Name
(2R)-2-Methyl-4,5-dideoxy
Status
Investigative
Structure
Formula
C7H15O7P
InChI
1S/C7H15O7P/c1-5(7(9)10)6(8)3-2-4-14-15(11,12)13/h5-6,8H,2-4H2,1H3,(H,9,10)(H2,11,12,13)/t5-,6+/m1/s1
InChIKey
MQRCYOMQUQMVCH-RITPCOANSA-N
PubChem CID
11064567
TTD Drug ID
D0P9DD
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Phosphogluconate dehydrogenase (PGD)
YTH domain-containing family protein 2 (YTHDF2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Phosphogluconate dehydrogenase (PGD) is a therapeutic target for (2R)-2-Methyl-4,5-dideoxy. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of (2R)-2-Methyl-4,5-dideoxy through regulating the expression of Phosphogluconate dehydrogenase (PGD). [1], [2]
References
Ref 1 YTH domain family 2 promotes lung cancer cell growth by facilitating 6-phosphogluconate dehydrogenase mRNA translation. Carcinogenesis. 2020 Jul 10;41(5):541-550. doi: 10.1093/carcin/bgz152.
Ref 2 Sugar derivatives as new 6-phosphogluconate dehydrogenase inhibitors selective for the parasite Trypanosoma brucei. Bioorg Med Chem. 2003 Apr 3;11(7):1207-14. doi: 10.1016/s0968-0896(02)00650-8.